Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion?

Amgen (AMGN) and AstraZeneca (AZN) reported positive late-stage trial results for their combination therapy, Imdelltra and Imfinzi, in extensive-stage small-cell lung cancer. The treatment improved overall survival, progression-free survival, and response rates. Imdelltra generated $513M in sales last year, and the results could expand its use. Amgen's Q2 2026 revenue rose 10%, while AstraZeneca faces investor pressure from recent setbacks.

The FDA approved Etcamah for advanced breast cancer patients with ESR1 mutations, extending progression-free survival to 16 months vs. 9.2 months with hormone therapy alone. The drug is used with CDK4/6 inhibitors and requires a companion blood test, Guardant360 CDx. AstraZeneca markets Etcamah, which received accelerated approval pending further survival data.

AstraZeneca reported phase 3 trial results showing Imfinzi plus Imdelltra improved overall survival in extensive-stage small cell lung cancer (ES-SCLC) compared to Imfinzi alone. The trial involved patients who had not progressed after initial treatment. AstraZeneca plans to present the data at a medical meeting and share it with regulators. Imfinzi is already approved in multiple countries for SCLC treatment.

Amgen (AMGN) and AstraZeneca (AZN) reported positive phase III study results for their lung cancer drug combination, Imdelltra and Imfinzi, showing improved overall and progression-free survival. The study, DeLLphi-305, evaluated the combination against Imfinzi alone in extensive-stage small-cell lung cancer (SCLC) patients. Both companies highlighted the potential market opportunity, with SCLC accounting for 15% of lung cancers and an estimated 195,000 global cases in 2026. Imdelltra's sales re

AstraZeneca's oral SERD combination therapy, Etcamah, received FDA approval for HR-positive, HER2-negative advanced breast cancer after a Phase 3 trial showed a 56% reduction in disease progression risk. The trial used circulating tumor DNA to monitor ESR1 mutations, allowing early treatment changes. This is AstraZeneca's 10th FDA approval in 2026.

Deutsche Bank assigned a Sell rating to AstraZeneca PLC. The rating is based on a weighted average of valuation, EPS revisions, and visibility metrics. Berenberg reiterated its Buy rating earlier. The stock has seen a 0.67% increase over 5 days but a 14.94% decrease year-to-date.